The company's innovative technology enables the testing of thousands of molecules directly on primary cells sampled from patients with inborn errors of metabolism, allowing for the rapid identification of molecules that specifically correct the patient's molecular defect and provide a new opportunity for a cure. APTEEUS aims to provide clinicians and their patients with an innovative service of clinical biology that meets the emerging challenge of individualized medicine, particularly for those suffering from orphan diseases.